PAUL H PEVSNER
Medical Practice in New York, NY
License number
New Jersey 25MA05966900
Issued Date
Feb 8, 1993
Expiration Date
Jun 30, 2017
Category
Medical Examiners
Type
Medical Doctor
Address
Address
New York, NY
Personal information
See more information about PAUL H PEVSNER at radaris.comName
Address
Phone
157 E 57Th St Ph B, New York, NY 10022
367 62Nd St, New York, NY 10021
515 89Th St, New York, NY 10128
PO Box 2268, New York, NY 10021
Professional information
Associate Professor At Nyu School Of Medicine
Position:
Associate Professor at NYU School of Medicine
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
NYU School of Medicine
-
Associate Professor
University of Missouri School of Medicine
2009 - 2011
-
Adjunct Professor of Pathology and Anatomical Sciences
Dr. Paul H Pevsner, New York NY - MD (Doctor of Medicine)
Specialties:
Diagnostic Radiology
Address:
157 E 57Th St, New York 10022
(917) 514-3339 (Phone)
367 E 62Nd St, New York 10065
(917) 514-3339 (Phone)
367 E 62Nd St, New York 10065
Certifications:
Diagnostic Radiology, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Rosalind Franklin University of Medicine and Science / Chicago Medical School
Graduated: 1965
University Of Minnesota
Johns Hopkins
Rosalind Franklin University of Medicine and Science / Chicago Medical School
Graduated: 1965
University Of Minnesota
Johns Hopkins
Paul Pevsner, New York NY
Specialties:
Neuro-Radiologist
Address:
157 E 57Th St, New York, NY 10022
Methods For Direct Biomolecule Identification By Matrix-Assisted Laser Desorption Ionization (Maldi) Mass Spectrometry
US Patent:
7714276, May 11, 2010
Filed:
Sep 29, 2006
Appl. No.:
11/541380
Inventors:
Paul Pevsner - New York NY, US
Frederick Naftolin - Woodbridge CT, US
Douglas C. Miller - Delle Mead NJ, US
Dean Hillman - New Hyde Park NY, US
Brian K. Stall - Bedford NH, US
Steven M. Wishnie - Columbia MD, US
Frederick Naftolin - Woodbridge CT, US
Douglas C. Miller - Delle Mead NJ, US
Dean Hillman - New Hyde Park NY, US
Brian K. Stall - Bedford NH, US
Steven M. Wishnie - Columbia MD, US
Assignee:
New York University - New York NY
International Classification:
B01D 59/44
US Classification:
250282, 250287
Abstract:
The present invention relates to the use of post source decay (PSD) or collision induced dissociation (CID) direct tissue (DT) MALDI-TOF or DT-MALDI-TOF-TOF mass spectrographic identification of biological molecules in a tissue or cellular sample without the need for further protein extraction. This method provides for studying cells or tissues by direct tissue MALDI (DT-MALDI), thereby substituting in situ protein release for further protein extraction. Mass/intensity data was processed with Mascot© software interrogation of the NCBI database. These results are proof of principle that DT-MALDI, combined with bioinformatics, can directly identify proteins in cells and tissues from their mass spectra.
Biomarkers Of Ionizing Radiation
US Patent:
8269163, Sep 18, 2012
Filed:
May 4, 2009
Appl. No.:
12/387508
Inventors:
Paul H. Pevsner - New York NY, US
Assignee:
New York University - New York NY
International Classification:
B01D 59/44, H01J 49/00
US Classification:
250282, 250281, 250287, 250288, 435 6, 435 7, 43510821, 435194
Abstract:
The present invention provides novel radiation associated markers. The radiation associated markers may be one or more of albumin, LTGF-β, or any protein or peptide listed in any one of Tables 1, 2, 3, 4, 5, and 6 provided herein. The present invention also provides methods of assessing exposure to ionizing radiation by determining the presence of one or more radiation associated markers. The methods may optionally include quantifying one or more of the radiation associated markers. The methods may further include comparing the amount of one or more radiation associated markers in the sample determined to be present in the sample with either (i) the amount determined for temporally matched, normal samples or (ii) the amount determined for samples obtained from individuals or subjects that have not been exposed to an elevated level of ionizing radiation. The present invention further provides a method of predicting outcome in a subject after exposure to elevated levels of ionizing radiation. Further, the present invention provides a method of determining the amount of radiation therapy that has been delivered to a particular tissue.
Methods For Direct Biomolecule Identification By Matrix-Assisted Laser Desorption Ionization (Maldi) Mass Spectrometry
US Patent:
8525104, Sep 3, 2013
Filed:
Apr 27, 2010
Appl. No.:
12/799576
Inventors:
Paul Pevsner - New York NY, US
Frederick Naftolin - Woodbridge CT, US
Douglas C. Miller - Belle Mead NJ, US
Dean Hillman - New Hyde Park NY, US
Brian K. Stall - Bedford NH, US
Steven M. Wishnies - Columbia MD, US
Frederick Naftolin - Woodbridge CT, US
Douglas C. Miller - Belle Mead NJ, US
Dean Hillman - New Hyde Park NY, US
Brian K. Stall - Bedford NH, US
Steven M. Wishnies - Columbia MD, US
Assignee:
New York University - New York NY
International Classification:
B01D 59/44, H01J 49/00, H01J 49/40
US Classification:
250281, 250288, 250282
Abstract:
The present invention relates to the use of post source decay (PSD) or collision induced dissociation (CID) direct tissue (DT) MALDI-TOF or DT-MALDI-TOF-TOF mass spectrographic identification of biological molecules in a tissue or cellular sample without the need for further protein extraction. This method provides for studying cells or tissues by direct tissue MALDI (DT-MALDI), thereby substituting in situ protein release for further protein extraction. Mass/intensity data was processed with Mascot© software interrogation of the NCBI database. These results are proof of principle that DT-MALDI, combined with bioinformatics, can directly identify proteins in cells and tissues from their mass spectra.
Methods For Predicting Embryo Viability
US Patent:
2009007, Mar 19, 2009
Filed:
Sep 5, 2008
Appl. No.:
12/231894
Inventors:
Paul H. Pevsner - New York NY, US
Frederick Naftolin - New York NY, US
Jamie Grifo - New York NY, US
Fred Licciardi - New York NY, US
Frederick Naftolin - New York NY, US
Jamie Grifo - New York NY, US
Fred Licciardi - New York NY, US
International Classification:
G01N 33/53, C12Q 1/02
US Classification:
435 71, 435 29
Abstract:
The present invention provides methods for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence or absence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample. In many instances, the invention is applicable to embryos generated by in vitro fertilization techniques, for instance, to embryos developing in a growth media. The present invention further provides methods for determining the amount of a pregnancy associated markers such as molecular isoforms of hCG (hCG) in a sample. The present invention also provides a diagnostic kit for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample.
Methods For Preparation Of Live Body Tissues For Examination
US Patent:
2007011, May 17, 2007
Filed:
Sep 28, 2006
Appl. No.:
11/541403
Inventors:
Paul Pevsner - New York NY, US
Frederick Naftolin - Woodbridge CT, US
Ahmed Metwaly - New Haven CT, US
Erol Gulcicek - Madison CT, US
Frederick Naftolin - Woodbridge CT, US
Ahmed Metwaly - New Haven CT, US
Erol Gulcicek - Madison CT, US
International Classification:
A61K 51/00, A01N 1/02, A61K 49/04, C12Q 1/00
US Classification:
424001110, 424009400, 435001100, 435004000
Abstract:
A minimally invasive procedure for perfusion-impregnation of tissues, organs and cells is provided that aids in the retention of tissue and cellular architecture without the formation of artifacts. The procedure allows for monitoring drug disposition, for detecting diseased tissue and for monitoring the presence of target molecules in a sample using various imaging techniques, including matrix assisted laser desorption ionization mass spectrometry (MALDI-MS).
Methods For Detecting Colon Carcinoma
US Patent:
2009017, Jul 2, 2009
Filed:
Dec 11, 2008
Appl. No.:
12/316374
Inventors:
Paul H. Pevsner - New York NY, US
International Classification:
G01N 33/574, G01N 33/68, G01N 33/72, C12Q 1/32, G01N 33/566
US Classification:
435 723, 436 86, 436 66, 435 26, 436501
Abstract:
The present invention provides methods for diagnosing carcinoma, providing a prognosis for a carcinoma or assessing the likelihood that a tissue may become cancerous by identifying the presence or absence of or determining the amount of one or more carcinoma associated markers. Further, the present invention provides methods for determining whether a tissue should be surgically resected and for determining the territorial extent of resection. The carcinoma markers may be those provided in FIG. The present invention also provides a diagnostic kit for diagnosing carcinoma, providing a prognosis for a carcinoma or assessing the likelihood that a tissue may become cancerous by identifying the presence of or determining the amount of one or more carcinoma associated markers. The methods and kits are especially useful regarding colon, rectal or colorectal carcinoma.
Gold Coated Lanthanide Nanoparticles
US Patent:
2013000, Jan 3, 2013
Filed:
Jan 3, 2012
Appl. No.:
13/342823
Inventors:
John David Robertson - Columbia MO, US
Mark F. McLaughlin - Columbia MO, US
Paul H. Pevsner - New York NY, US
Mark F. McLaughlin - Columbia MO, US
Paul H. Pevsner - New York NY, US
Assignee:
THE CURATORS OF THE UNIVERSITY OF MISSOURI - Columbia MO
International Classification:
A61K 51/12, A61P 35/00, B05D 5/00, B82Y 5/00, B82Y 40/00
US Classification:
424 129, 427 214, 977773, 977890, 977915
Abstract:
The present invention is directed α-particle emitting nanoparticles that comprise a lanthanide phosphate sequestration shell enclosing an α-emitting-radioisotope-doped lanthanide phosphate core such that the shell allows at least some of the α emissions from the α-emitting radioisotope to pass therethrough and prevents at least some radioactive decay products of the α-emitting radioisotope from exiting the α-particle emitting nanoparticle. Further, such α-particle emitting nanoparticles may be coated with gold and functionalized. Additionally, a method for making and using the same are disclosed.